Phospholipase A2: A Promising Drug Target for Various Diseases

Target Name: Phospholipase A2, Cytosolic

NCBI ID: P10890

Phospholipase A2, Cytosolic

Other Name(s): cPLA2 | Phospholipase A2, Cytosolic

Phospholipase A2: A Promising Drug Target for Various Diseases

Phospholipase A2 (PLA2) is a protein that is expressed in various cell types throughout the body. It is a key enzyme in the phosphatidyl choline (PA) signaling pathway, which is involved in the regulation of many cellular processes, including cell signaling, inflammation, and intracellular signaling. PLA2 has also been implicated in the development and progression of various diseases, including cardiovascular disease, neurodegenerative diseases, and cancer.

One of the subtypes of PLA2 is the cytosolic (nonspecific) subtype (cPLA2). The cytosolic subtype is the most abundant form of PLA2 and is expressed in most tissues and cells. It is involved in the production of PA, which is a key component of cell membranes and plays a central role in cellular signaling and communication.

The cytosolic subtype of PLA2 is a good candidate for drug targeting, due to its involvement in the production of PA, which is often referred to as "signaling lipid" or "permeable signaling molecule". PA is a highly responsive molecule, as changes in its levels can have a significant impact on cellular signaling pathways. Additionally, the cytosolic subtype of PLA2 is also involved in the regulation of the formation and function of the cellular endomembrane system, which is important for the development and progression of various diseases.

One of the key functions of the cytosolic subtype of PLA2 is its role in the production of the phospholipid phosphatidylcholine (PC). PC is a key component of the cell membrane and plays a central role in cellular signaling and communication. The cytosolic subtype of PLA2 is involved in the production of PC, which is the first step in the production of PA.

Another function of the cytosolic subtype of PLA2 is its role in the regulation of cellular signaling pathways. PLA2 has been shown to be involved in the regulation of many cellular signaling pathways, including the TGF-β pathway, the PI3K pathway, and the NF-kappa-B pathway. Additionally, the cytosolic subtype of PLA2 is also involved in the regulation of cellular adhesion, which is important for the development and progression of various diseases, including cancer.

The cytosolic subtype of PLA2 is also involved in the regulation of cellular inflammation. PLA2 has been shown to be involved in the regulation of cellular inflammation, including the production of pro-inflammatory cytokines. Additionally, the cytosolic subtype of PLA2 is also involved in the regulation of cellular apoptosis, which is important for the development and progression of various diseases, including neurodegenerative diseases.

In conclusion, the cytosolic (nonspecific) subtype of PLA2 is a promising drug target for the development of various diseases. Its involvement in the production of PA, the regulation of cellular signaling pathways, the regulation of cellular inflammation, and the regulation of cellular apoptosis make it an attractive target for drug development. Additionally, the cytosolic subtype of PLA2 may also be a biomarker for the diagnosis and prognosis of various diseases.

Protein Name: Phospholipase A2, Cytosolic (nonspecified Subtype)

The "Phospholipase A2, Cytosolic Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Phospholipase A2, Cytosolic comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets